

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Hepatocellular Carcinoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following statements best describes the results from the Phase III IMbrave150 trial evaluating the efficacy and safety of atezolizumab in combination with bevacizumab versus sorafenib alone for patients with untreated locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC)?
 - A significant improvement in overall survival (OS) on the atezolizumab/bevacizumab arm but no difference in progression-free survival (PFS) between the arms
 - A significant improvement in PFS on the atezolizumab/bevacizumab arm but no difference in OS between the arms
 - A significant improvement in both OS and PFS on the atezolizumab/bevacizumab arm
- Based on the results of the CheckMate 040 trial, which of the following combination strategies is FDA approved as second-line therapy for patients with HCC who have previously received sorafenib?
 - Nivolumab/ipilimumab
 - Nivolumab/sorafenib
 - Lenvatinib/pembrolizumab
- Which of the following regimens are being investigated as first-line therapy for patients with advanced HCC in the ongoing Phase III LEAP-002 trial?
 - Nivolumab/lenvatinib versus lenvatinib
 - Pembrolizumab/cabozantinib versus cabozantinib
 - Atezolizumab/sorafenib versus sorafenib
 - Pembrolizumab/lenvatinib versus lenvatinib
- Which of the following statements is true about the effect of systemic corticosteroid therapy on outcomes with immune checkpoint inhibitor therapy for patients with HCC?
 - The use of corticosteroids may alter the antitumor effect of immune checkpoint inhibitors
 - The use of corticosteroids has no effect on the antitumor effect of immune checkpoint inhibitors
- Which drug type best reflects the mechanism of action of sintilimab, currently undergoing investigation with a bevacizumab biosimilar versus sorafenib alone as first-line therapy for advanced HCC in the ORIENT-32 trial?
 - Anti-VEGF monoclonal antibody
 - Anti-PD-1 monoclonal antibody
 - Anti-CTLA-4 monoclonal antibody
 - Anti-PD-L1 monoclonal antibody